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Más  allá  de los  parámetros  lipídicos  tradicionales  en la enfermedad  renal
crónica
Cardiovascular morbidity and mortality in chronic kidney dis-
ease (CKD) patients remain unacceptably high, as evidenced
by large epidemiological studies and registries of renal
patients from the Spanish autonomous communities and
world-wide.1
Both etiology and clinical manifestations have differential
aspects compared to the general population. CKD patients
have accelerated atheromatosis and ischemic events from
early stages of the disease. However, contrary to the general
population, the  implications of lipid alterations are controver-
sial.
First, the lipids of patients with CKD show a different
profile from the dyslipidemia of the general population, and
it varies with the severity of renal dysfunction. In CKD,
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lipid abnormalities are characterized by hypertriglyceridemia,
variable levels of LDL-cholesterol and low levels of HDL-
cholesterol. In early CKD stages, there are high levels of
LDL-cholesterol, but in more  advanced stages this parame-
ter is normalized or even reduced.2 The National Observatory
of Atherosclerosis in  Nephrology (the NEFRONA Study)3,4
observed a  progressive decrease of total cholesterol, LDL-
cholesterol, HDL-cholesterol and non-HDL-cholesterol that
are proportional to the stage of renal disease. (Fig. 1).
Second, renal patients have a higher burden of athero-
matosis than the general population, and it increases with  the
severity of renal dysfunction.5 In addition, they show a  more
rapid progression of atherosclerosis, particularly in advanced
CKD stages.6a Atheromatosis is  not only a predictor of vascular
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Fig. 1 – Traditional lipid parameters in  CKD.
Data obtained from the NEFRONA study.5 Values are expressed as mean ± standard error.
events, it is a vascular disease in itself, and as recently stated
by the European Society of Atherosclerosis, LDL-cholesterol is
an ethiological factor. In fact, high LDL-cholesterol is  a  con-
dition necessary for the development of a  sequence of events
leading to the formation of the atherosclerotic plaque, whose
growth or rupture is  the final trigger of the vascular event
itself.6b
Third, studies on therapeutic interventions increased the
controversy. Statins, lipid-lowering drugs with highly demon-
strated effectiveness in the general population, appeared to
be less effective in patients with CKD. The well known stud-
ies 4D7 and AURORA8 failed to demonstrate the effectiveness
of statins in dialysis patients. In addition, the  SHARP study
reinforced this idea, although it showed that in non-dialysis
CKD patients, statins did reduce vascular risk. Hofwever, this
reduction decreased as  renal function declines.9 It is  impor-
tant to bear in  mind when analysing these results that the
above studies have some specific circumstances and limita-
tions. Nonetheless, their results and conclusions have been
reproduced many times, and have been strengthened by the
publication of multiple meta-analyzes 10–13
In addition, a debate has been generated by the latest
American guidelines of vascular risk, which were also sup-
ported by the  2013 KDIGO guidelines on the management of
dyslipidemia in  CKD. In both guidelines, a  paradigm change
was promulgated in the management of lipid disorders and
the prevention of vascular events. They encourage the use
of pharmacological treatment based on the patient’s risk
profile and omitting LDL-cholesterol values. The guidelines
are summarized in the following points. First, it is recom-
mended to  study the  lipid profile of all patients with CKD
of any stage. Most do not require follow-up controls. Second,
it is recommended to initiate statin or statin /  ezetimibe in
CKD patients over 50 years of age not on dialysis. Third, in
patients under 50 years of age not on dialysis and renal trans-
plants of any age, it is suggested to treat only if they have a
history of cardio or cerebrovascular event, diabetes or an  esti-
mated 10-year risk of cardiovascular event greater than 10%.
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Fig. 2 – Traditional and non-traditional lipid parameters.
The traditional lipid parameters are based on total cholesterol, LDL-cholesterol, HDL-cholesterol, non-HDL-cholesterol and
triglycerides. However, non-traditional parameters such as the lipidoma, particle size and number of particles along with
lipoprotein(a) and PCSK9 levels would provide more  accurate information about the vascular risk of CKD patients.
In both cases, the  indication for treatment is not guided by
LDL-cholesterol level, and dislipemia follow-ups are not rec-
ommended. Finally, in  patients on dialysis, it is not  suggested
to initiate lipid-lowering treatment.14
These recommendations were received with unequal reac-
tions, especially the  one that refers to no need for follow-up
lab measurements, an  strategy of “shoot and forget”. This is
similar to what was suggested months before by the Ameri-
can College of Cardiology and the American Heart Association
for the general population.15 This disturbing change was soon
rejected by many European scientific societies as well as by
many  American experts. However, having no intention to
make an analysis in detail of these statements, they reflect a
gap between physicians who  are faced with risk management
and vascular prevention.
The latest European guidelines of the European Society
of Cardiology and the  European Association of Atheromato-
sis of 2016 classify patients with CKD as subjects with
moderate vascular risk (if the estimated glomerular filtra-
tion rate (eGFR) is 30–59 mL/min/1.73 m2) or severe (if the
eGFR < 30 mL/min/1.73 m2).16 This classification has  therapeu-
tic implications since it sets the target LDL-cholesterol levels
in 100 or 70 mg/dL, respectively.
All this controversies have generated different ideas and
heterogeneity in clinical practice in relation to  the  diagnosis,
treatment and the assessment of the contribution of dis-
lipemia to the cardiovascular morbidity in these patients.
Historically, the lipid parameters measured in clini-
cal practice were: total cholesterol, LDL-cholesterol, HDL-
cholesterol and triglycerides. However, in recent years the
limited contribution of these parameters in the renal popu-
lation has become evident (Fig. 2).
In CKD patients, the nearly normal or  low levels of
LDL-cholesterol do not explain the fast progression and ele-
vated atheromatous burden6a,17, and the  considerable residual
risk.13
Nowadays, there are new approaches to analyze the  differ-
ent subpopulations of lipoproteins; among many  options, the
most common are: gel electrophoresis, density gradient ultra-
centrifugation and nuclear magnetic resonance.18 Briefly, each
method determines different physicochemical parameters of
lipoproteins such as size, electrical charge, cholesterol con-
centration or the magnetic resonance to assess the lipoprotein
subclass distribution.19
Based on the current knowledge, we propose a  new
approach to the management of lipid abnormalities in  CKD
patients; the idea is  to identify specific therapeutic targets
in this population. It is fundamental for clinicians to  know
what is measured in  a  routine lipid profile. The parameter
“LDL-cholesterol” or “HDL-cholesterol” reflects the concen-
tration of cholesterol transported in molecules called LDL or
HDL, respectively. However, cholesterol may be  transported
in a variable number of LDL or HDL particles, thus the load
of cholesterol per particle would not be the same. Therefore,
it makes sense, to measure the concentration of LDL  and
HDL particles (LDL-P and HDL-P); individuals with the  same
LDL-cholesterol may  have different vascular risk if they have
different particle concentration. The individual with higher
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LDL-P has higher cardiovascular risk.20 Conversely, a  high
HDL-P correlates with a  reduced vascular risk.21 The size of
the particle is relevant. Multiple studies have shown that small
LDL particles are more  atherogenic than large ones since they
have an increased ability to  penetrate the vascular wall.22
Similarly, small HDL particles also correlate with a  higher vas-
cular risk due to a  decreased anti-atherogenic effect.23 Renal
patients have an accumulation of small LDL particles that
are associated with a  higher rate of cardiovascular events.24,25
Interestingly, they show a decrease in small pro-atherogenic
HDL particles.26 Paradoxically, these parameters of consider-
able clinical relevance are currently not determined in daily
clinical practice although their use in research is  becoming
widespread.
Lipoprotein (a) [Lp (a)] is  one parameter easy to obtain from
the clinical Lab. It has been demonstrated that the levels of
Lp(a) increase as  kidney disease progresses27 and decline after
kidney transplantation.28 An in vivo study showed a decrease
in the clearance of Lp(a) in  hemodialysis patients, demon-
strating the involvement of the kidney in its elimination.29
Unlike patients on hemodialysis, patients with nephrotic
syndrome have an increased hepatic synthesis of Lp(a) result-
ing in an elevation of plasma levels.30 Lp(a) has a marked
proatherogenic effect.31 Lp(a) predicts the development of
carotid atheromatous disease32,33 and vascular events in dial-
ysis patients.34 However, the determination of Lp(a) is not
widespread, which can be explained by the absence of drugs
capable to modify Lp(a) levels.
Historically, available drugs only aimed to  modify the con-
centration of LDL-cholesterol. There were no treatments with
a significant effect on other lipid parameters (aside from
apheresis). On the other hand, PCSK9 inhibitors offer a  new
therapeutic approach. They have the ability to  reduce of LDL
cholesterol levels and the risk of vascular events.35 Moreover,
they also reduce the  plasma concentration of Lp(a).36 It should
be emphasized that these new drugs exert an impact on the
size of the particles. They reduce the total concentration of LDL
particles and also cause a  reduction of large and small LDL par-
ticles. Surprisingly, they increase the number of HDL particles,
especially the larger ones.37 Unfortunately, in Nephrology, we
do not have specific studies that evaluate the impact of these
treatments in  patients with CKD. A  priori, given their benefi-
cial effect on parameters altered in CKD, it is  easy to expect
positive results. Based on that, the nephrology community
need to design clinical trials in  such population.
Meanwhile, it is  urgent to gain further information about
specific lipid abnormalities in renal patients. Besides the
quantitative changes described above, CKD is  characterized by
qualitative changes caused by a highly inflammatory and pro-
oxidative state.38 New research tools, such as metabolomics
and lipidomics, are useful to  investigate lipid abnormalities
in CKD patients. There are reasons to believe that during the
next coming years, we  will  witness a resurgence of the field of
dyslipidemia in Nephrology, with new perspectives and more
effective tools.
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